Oct 30, 2024 / 01:00PM GMT
Martine Rothblatt - United Therapeutics Corp - Founder, Chairperson, and Chief Executive Officer
In 2025 we expect FDI action on our recently submitted pre market approval application for our centralized long evaluation systems or see less ex-vivo lung perfusion technology.
Beyond our record-setting commercial performance, we expect a steady stream of clinical data readouts and regulatory actions through the next 36 months, setting our company up well for continued growth through the balance of the decade.
Our revolution wave is also making tangible progress toward reality. With our Phase one study for Mirel, liver E lap now underway the first clinical study of a bioengineered organ alternative.
We expect data from this initial safety study in 2025. Also within our revolution way, we recently received feedback from the FDA regarding our IND for new kidney 10 gene, added xeno kidney and we expect to track to file our IND shortly for what will be the first clinical study of xeno organ.
We look forward to sharing more details on our clinical trial design and commercial
Q3 2024 United Therapeutics Corp Earnings Call Transcript
Oct 30, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers